{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:02:14Z","timestamp":1790395334378,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2017R1D1A1B03034649"],"award-info":[{"award-number":["2017R1D1A1B03034649"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2014R1A5A2009936"],"award-info":[{"award-number":["2014R1A5A2009936"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.canlet.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T14:04:35Z","timestamp":1584021875000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models"],"prefix":"10.1016","volume":"478","author":[{"given":"Jung Hwa","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Dong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Tae","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Tae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa Kyoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.03.009_bib1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMcibr1309402","article-title":"Angiogenesis in glioblastoma","volume":"369","author":"Das","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2020.03.009_bib3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMe1313309","article-title":"Bevacizumab in glioblastoma--still much to learn","volume":"370","author":"Fine","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0940-2993(11)80292-7","article-title":"Vascular morphology and angiogenesis in glial tumors","volume":"47","author":"Plate","year":"1995","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.canlet.2020.03.009_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1634\/theoncologist.2008-0272","article-title":"Angiogenesis as a therapeutic target in malignant gliomas","volume":"14","author":"Chi","year":"2009","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2020.03.009_bib6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.03.009_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.03.009_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2020.03.009_bib9","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/sj.onc.1203035","article-title":"New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF","volume":"18","author":"Holash","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.03.009_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1248\/bpb.25.1049","article-title":"Prolyl endopeptidase inhibitors from the roots of Lindera strychnifolia F. Vill","volume":"25","author":"Kobayashi","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.canlet.2020.03.009_bib11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1021\/np100874f","article-title":"Secondary metabolites from the roots of Neolitsea daibuensis and their anti-inflammatory activity","volume":"74","author":"Wong","year":"2011","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.canlet.2020.03.009_bib12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3892\/mmr.2014.2015","article-title":"Isolinderalactone inhibits proliferation of A549 human nonsmall cell lung cancer cells by arresting the cell cycle at the G0\/G1 phase and inducing a Fas receptor and soluble Fas ligand-mediated apoptotic pathway","volume":"9","author":"Chang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2020.03.009_bib13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3892\/or.2015.4503","article-title":"Isolinderalactone enhances the inhibition of SOCS3 on STAT3 activity by decreasing miR-30c in breast cancer","volume":"35","author":"Yen","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2020.03.009_bib14","first-page":"4690","article-title":"Anti-metastatic effects of isolinderalactone via the inhibition of MMP-2 and up regulation of NM23-H1 expression in human lung cancer A549 cells","volume":"15","author":"Chuang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.canlet.2020.03.009_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2018.11.027","article-title":"Isolinderalactone regulates the BCL-2\/caspase-3\/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model","volume":"443","author":"Hwang","year":"2019","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.03.009_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2014.07.014","article-title":"MJ-66 induces malignant glioma cells G2\/M phase arrest and mitotic catastrophe through regulation of cyclin B1\/Cdk1 complex","volume":"86","author":"Liu","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.canlet.2020.03.009_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nprot.2006.102","article-title":"Sample extraction techniques for enhanced proteomic analysis of plant tissues","volume":"1","author":"Isaacson","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2020.03.009_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.3892\/or.2015.4223","article-title":"Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation","volume":"34","author":"Yang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2020.03.009_bib19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nm889","article-title":"SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier","volume":"9","author":"Lee","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10456-018-9647-0","article-title":"Perfused 3D angiogenic sprouting in a high-throughput in vitro platform","volume":"22","author":"van Duinen","year":"2019","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2020.03.009_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0360-3016(84)90301-8","article-title":"Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data","volume":"10","author":"Moulder","year":"1984","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2020.03.009_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2020.03.009_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.03.009_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/emmm.201101107","article-title":"Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF","volume":"4","author":"Lee","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","article-title":"Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype","volume":"10","author":"Holmquist-Mengelbier","year":"2006","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.03.009_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2020.03.009_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2020.03.009_bib32","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Canc. Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520301282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520301282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:46:46Z","timestamp":1759592806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520301282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"alternative-id":["S0304383520301282"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.03.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}